A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein

ABSTRACT Untreated rabies virus (RABV) infection leads to death. Vaccine and postexposure treatment have been effective in preventing RABV infection. However, due to cost, rabies vaccination and treatment have not been widely used in developing countries. There are 55,000 human death caused by rabies annually. An efficacious and cost-effective rabies vaccine is needed. Parainfluenza virus 5 (PIV5) is thought to contribute to kennel cough, and kennel cough vaccines containing live PIV5 have been used in dogs for many years. In this work, a PIV5-vectored rabies vaccine was tested in mice. A recombinant PIV5 encoding RABV glycoprotein (G) (rPIV5-RV-G) was administered to mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation. The vaccinated mice were challenged with a 50% lethal challenge dose (LD50) of RABV challenge virus standard 24 (CVS-24) intracerebrally. A single dose of 106 PFU of rPIV5-RV-G was sufficient for 100% protection when administered via the i.n. route. The mice vaccinated with a single dose of 108 PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%). Intriguingly, the mice vaccinated orally with a single dose of 108 PFU of rPIV5-RV-G showed a 50% survival rate, which is comparable to the 60% survival rate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE. This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate that rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines.

[1]  Z. Fu,et al.  Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5 , 2012, PloS one.

[2]  S. Tompkins,et al.  Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice , 2012, Journal of Virology.

[3]  S. Tompkins,et al.  Recombinant Parainfluenza Virus 5 Expressing Hemagglutinin of Influenza A Virus H5N1 Protected Mice against Lethal Highly Pathogenic Avian Influenza Virus H5N1 Challenge , 2012, Journal of Virology.

[4]  Todd G. Smith,et al.  From brain passage to cell adaptation: the road of human rabies vaccine development , 2011, Expert review of vaccines.

[5]  B. He,et al.  Sumoylation of the P Protein at K254 Plays an Important Role in Growth of Parainfluenza Virus 5 , 2011, Journal of Virology.

[6]  Hualan Chen,et al.  Newcastle Disease Virus-Vectored Rabies Vaccine Is Safe, Highly Immunogenic, and Provides Long-Lasting Protection in Dogs and Cats , 2011, Journal of Virology.

[7]  Pradeep Kota,et al.  Automated minimization of steric clashes in protein structures , 2011, Proteins.

[8]  Hualei Wang,et al.  Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination , 2010, Journal of Virology.

[9]  J. Christopher-Hennings,et al.  Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in porcine reproductive and respiratory syndrome virus infected cells: nsp1 function as interferon antagonist , 2009, Virology.

[10]  C. Rupprecht,et al.  Poxvirus-vectored vaccines for rabies--a review. , 2009, Vaccine.

[11]  K. Murray,et al.  Rabies in vaccinated dogs and cats in the United States, 1997-2001. , 2009, Journal of the American Veterinary Medical Association.

[12]  B. Dietzschold,et al.  Immunogenicity and Safety of Recombinant Rabies Viruses Used for Oral Vaccination of Stray Dogs and Wildlife , 2009, Zoonoses and public health.

[13]  S. Ostroff,et al.  Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[14]  A. Schmitt,et al.  A Single Amino Acid Residue Change in the P Protein of Parainfluenza Virus 5 Elevates Viral Gene Expression , 2008, Journal of Virology.

[15]  C. Jallet,et al.  Canine adenovirus based rabies vaccines. , 2008, Developments in biologicals.

[16]  S. Nadin-Davis,et al.  ERA VACCINE-DERIVED CASES OF RABIES IN WILDLIFE AND DOMESTIC ANIMALS IN ONTARIO, CANADA, 1989–2004 , 2008, Journal of wildlife diseases.

[17]  R. Lamb,et al.  Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. , 2007, Virology.

[18]  C. Rupprecht,et al.  Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies. , 2007, Vaccine.

[19]  M. Schnell,et al.  A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. , 2006, Virology.

[20]  D. Slate,et al.  Current and future trends in the prevention, treatment and control of rabies , 2006, Expert review of anti-infective therapy.

[21]  Z. Fu,et al.  Rabies virus-induced apoptosis involves caspase-dependent and caspase-independent pathways. , 2006, Virus research.

[22]  Z. Xiang,et al.  A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  F. Monaco,et al.  Studies on an inactivated vaccine against rabies virus in domestic animals. , 2006, Developments in biologicals.

[24]  S. Finke,et al.  Replication strategies of rabies virus. , 2005, Virus research.

[25]  M. Meltzer,et al.  Re-evaluating the burden of rabies in Africa and Asia. , 2005, Bulletin of the World Health Organization.

[26]  C. Hanlon,et al.  Human infection due to recombinant vaccinia-rabies glycoprotein virus. , 2001, The New England journal of medicine.

[27]  Lindsay Martinez,et al.  Global infectious disease surveillance. , 2000 .

[28]  R. Lamb,et al.  Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. , 1997, Virology.

[29]  T. Hulland.  A Biographical History of Veterinary Pathology , 1997 .

[30]  K Fukaya,et al.  [Rabies virus]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[31]  Fishbein Db,et al.  Rationale and prospects for rabies elimination in developing countries , 1994 .

[32]  F. Meslin,et al.  Rationale and prospects for rabies elimination in developing countries. , 1994, Current topics in microbiology and immunology.

[33]  G. Turner,et al.  Rabies: a review. , 1993, Journal of comparative pathology.

[34]  R. Ruigrok,et al.  Rabies virus glycoprotein is a trimer , 1992, Virology.

[35]  H. Leblois,et al.  Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: a comparison. , 1992, Vaccine.

[36]  M. Whitt,et al.  Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein. , 1991, Virology.

[37]  W. A. Webster,et al.  Ineffectiveness and Comparative Pathogenicity of Attenuated Rabies Virus Vaccines for the Striped Skunk (Mephitis mephitis) , 1990, Journal of wildlife diseases.

[38]  C. Rupprecht,et al.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. B. Stewart,et al.  Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. , 1987, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[40]  R. Lathe,et al.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus , 1984, Nature.

[41]  R. Lathe,et al.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Dietzschold,et al.  Rabies virus glycoprotein. II. Biological and serological characterization , 1977, Infection and immunity.

[43]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[44]  George F. Dowdeswell,et al.  On rabies , 1888, Proceedings of the Royal Society of London.